[HTML][HTML] Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with …
A Corbeau, SC Kuipers, SM de Boer… - Radiotherapy and …, 2021 - Elsevier
Patients with locally advanced cervical cancer (LACC) treated with chemoradiation often
experience hematologic toxicity (HT), as chemoradiation can induce bone marrow (BM) …
experience hematologic toxicity (HT), as chemoradiation can induce bone marrow (BM) …
The impact of pelvic nodal radiotherapy on hematologic toxicity: A systematic review with focus on leukopenia, lymphopenia and future perspectives in prostate cancer …
GC Iorio, BO Spieler, U Ricardi, A Dal Pra - Critical reviews in oncology …, 2021 - Elsevier
Introduction Hematologic toxicity (HT), particularly leukopenia, is a common side-effect of
oncologic treatments for pelvic malignancies. Pelvic nodal radiotherapy (PNRT) has been …
oncologic treatments for pelvic malignancies. Pelvic nodal radiotherapy (PNRT) has been …
Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus …
A Dueñas-González, JJ Zarbá, F Patel… - Journal of Clinical …, 2011 - ascopubs.org
Purpose To determine whether addition of gemcitabine to concurrent cisplatin
chemoradiotherapy and as adjuvant chemotherapy with cisplatin improves progression-free …
chemoradiotherapy and as adjuvant chemotherapy with cisplatin improves progression-free …
Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy
Purpose: To identify dosimetric parameters associated with acute hematologic toxicity (HT)
and chemotherapy delivery in cervical cancer patients undergoing concurrent chemotherapy …
and chemotherapy delivery in cervical cancer patients undergoing concurrent chemotherapy …
Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer: an international multicenter phase II clinical trial …
LK Mell, I Sirák, L Wei, R Tarnawski… - International Journal of …, 2017 - Elsevier
Purpose To test the hypothesis that intensity modulated radiation therapy (IMRT) reduces
acute hematologic and gastrointestinal (GI) toxicity for patients with locoregionally advanced …
acute hematologic and gastrointestinal (GI) toxicity for patients with locoregionally advanced …
Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy
PURPOSE: To test the hypothesis that increased pelvic bone marrow (BM) irradiation is
associated with increased hematologic toxicity (HT) in cervical cancer patients undergoing …
associated with increased hematologic toxicity (HT) in cervical cancer patients undergoing …
Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer
PURPOSE: To compare bone marrow-sparing intensity-modulated pelvic radiotherapy (BMS-
IMRT) with conventional (four-field box and anteroposterior–posteroanterior [AP–PA]) …
IMRT) with conventional (four-field box and anteroposterior–posteroanterior [AP–PA]) …
Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix
MD Hasselle, BS Rose, JD Kochanski, SK Nath… - International Journal of …, 2011 - Elsevier
PURPOSE: To evaluate disease outcomes and toxicity in cervical cancer patients treated
with pelvic intensity-modulated radiation therapy (IMRT). METHODS AND MATERIALS: We …
with pelvic intensity-modulated radiation therapy (IMRT). METHODS AND MATERIALS: We …
Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis
F Petrelli, A De Stefani, F Raspagliesi, D Lorusso… - Gynecologic …, 2014 - Elsevier
Background Treatment with weekly cisplatin (CDDP) plus radiotherapy (RT) is the standard
regimen for stage IB to stage IVA cervical carcinoma (CC). We performed a systematic …
regimen for stage IB to stage IVA cervical carcinoma (CC). We performed a systematic …
[HTML][HTML] Radiosensitizers in cervical cancer. Cisplatin and beyond
M Candelaria, A Garcia-Arias, L Cetina… - Radiation …, 2006 - Springer
Cervical cancer continues to be a significant health burden worldwide. Globally, the majority
of cancers are locally advanced at diagnosis; hence, radiation remains the most frequently …
of cancers are locally advanced at diagnosis; hence, radiation remains the most frequently …